The CCAAT/enhancer binding protein alpha (C/EBP ) is an essential transcription factor for granulocytic differentiation. C/EBP mutations are found in approximately 8% of acute myeloid leukemia (AML) patients. Most of these mutations occur in the N-terminal coding region, resulting in a frame-shift and the enhanced translation of a dominant-negative 30-kDa protein, which may be responsible for the differentiation block observed in AML. To test this hypothesis, we introduced a cDNA encoding a N-terminal mutated C/EBP (mut10) into primary hematopoietic progenitors using a retroviral vector. Expression of mut10 in human
CD34
+ cord blood cells dramatically inhibited differentiation of both myeloid and erythroid lineages. Immunohistochemical analysis demonstrated co-expression of both myeloid and erythroid markers in the immature transformed cells. Surprisingly, mut10 did not block myelocytic differentiation in murine progenitors, but altered the differentiation kinetics and clonogenicity. Experiments were performed to confirmed that the differential effect of mut10 on murine and human progenitors was not due to species-specific differences in C/EBP protein sequences, expression levels, or inefficient targeting of relevant cells. Taken together, our results underline the intrinsic differences between hematopoietic controls in mouse and human and support the hypothesis that mutations in CEBPA are critical events in the disruption of myeloid differentiation in AMLs.
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Introduction
The hallmark of acute leukemia is the clonal, neoplastic proliferation of immature hematopoietic cells. The observed inhibition or complete arrest in differentiation can conceivably be due to an indirect mechanism, in which genetic mutations that disrupt cell cycle controls support proliferation at the expense of differentiation, and/or due to genetic abnormalities that directly interfere with the differentiation program. In support of the latter hypothesis, growing evidence suggests that the transcription factors that play pivotal roles in lineage-specific differentiation may be important targets of transformation in acute leukemias. 1 The B-ZIP transcription factor CCAAT/ enhancer binding protein (C/EBP ) and the ETS-family transcription factor PU.1 are two major regulators of myeloid differentiation. 2, 3 Unlike PU.1, which governs transcription of a wide spectrum of myeloid specific-genes found in both early hematopoietic stem cells and mature monocytes and granulocytes, C/EBPregulation has a more specific function in granulopoiesis. Indeed, C/EBP knock-out mice show a selective block in the differentiation of granulocytes, including neutrophils and eosinophils. 4 Furthermore, the constitutive expression of C/EBP in myeloid progenitors results in the induction of granulocytic development and partial inhibition of monocytic and erythroid development. [5] [6] [7] Several independent studies have demonstrated mutations in the CEBPA gene encoding C/EBP in approximately 8% of AML. [8] [9] [10] [11] These mutations are found primarily in AMLs with a myeloblast phenotype (FAB M1 and M2), consistent with the importance of C/EBP in granulocytic differentiation. In addition, these mutations are almost exclusively found in AMLs grouped as intermediate risk based on cytogenetic analysis. 8, 10, 11 The absence of mutations in AMLs within other risk groups associated with specific cytogenetic markers suggests that some genetic abnormalities may disrupt differentiation controls by interfering
For personal use only. on . by guest www.bloodjournal.org From with C/EBP regulation at different levels. This later hypothesis is supported by the finding that the AML1-ETO fusion product of t(8;21), a common cytogenetic abnormality within the favorable risk group, disrupts C/EBP function and thus the autoregulation of the CEBPA gene. 12, 13 Down-regulation of CEBPA might thus account for the impaired myeloid differentiation observed in primary hematopoietic cells expressing AML1-ETO. [14] [15] [16] [17] The CEBPA mutations can be largely divided into two groups: 1) C-terminal mutations that disrupt the basic zipper (B-ZIP) region, containing both DNA-binding as well as dimerization domains; 18 and 2) N-terminal mutations that disrupt the reading frame, resulting in premature termination of the normal 42-kDa and enhanced translation of a 30-kDa protein initiated at an internal AUG. The 30-kDa protein lacks the transactivating enhancers 1 and 2 (TE1 and TE2, also known to as TAD1 19, 20 ) and was shown to inhibit DNA binding and transactivation by wildtype C/EBP . 10 Thus whereas C-terminal mutations result in loss-of-function, 9,10 the N-terminal mutations give rise to a dominant negative protein.
Significantly, AML patients often carry both C-terminal and N-terminal CEBPA mutations, 11 suggesting that the proposed dominant-negative effect of the N-terminal mutant is weak, giving a selective advantage to cells that have lost the second allele.
To evaluate the significance and role of N-terminal CEBPA mutations in the development of AML, we expressed a C/EBP mutant in primary hematopoietic progenitors isolated from either human umbilical cord blood (CB) or murine bone marrow (BM) and evaluated its effect on differentiation. Our results underline intrinsic differences between hematopoietic controls in mouse and human and present strong evidence that mutations in CEBPA may be critical events leading to the disruption of myeloid differentiation observed in many AMLs.
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Materials and methods

Retroviral vectors and generation of infectious pseudotyped viral particles
Either C/EBP wild-type or mutant 10 (mut10) cDNAs 10 were cloned into the FMEV retroviral vector SF91-iGFP-PRE (FMEV-GFP; R780) 14 FMEV-YFP is similar to FMEV-GFP, except the eGFP coding sequence is replaced with that of the yellow fluorescent protein (eYFP, BD Biosciences, Heidelberg, Germany). To generate a CRE expression vector (FMEV-CRE), a cassette containing the SV40 promoter and the CRE coding region from MPEV-hyg -SV-CRE, 21 was placed downstream of the eGFP coding region in a MP91-GFP vector. Retroviral pseudotypes were prepared as previously described 14 with either the Env protein of the Moloney murine leukemia virus 22 (for infection of mouse cells) or the feline endogenous retrovirus RD114 23 (for infection of human cells).
To confirm excision of the Cebpa locus after CRE infection, PCR on genomic DNA was performed as previously described.
24
Enrichment of hematopoietic progenitors from murine BM and human CB cells, supplemented with 50 ng/ml mSCF, 10 ng mIL3, and 100 ng/ml each hFLT3 and IL11 for murine cells or in 100 ng/ml each hSCF and hFLT3 and 20 ng/ml each hIL6 and TPO for human cells. Recombinant mSCF and mIL3 were obtained from Strathman AG (Hamburg, Germany), all other recombinant growth factors were purchased from StemCell Technologies.
infections, and transplantation
Infections were carried in 6-well plates coated with RetroNectin® (CH-296; Cambrex Co., Verviers, Belgium), as previously described. 25, 26 For in vivo experiments, 1 x 10 6 murine cells were transplanted into lethally irradiated (9 Gy) B6-Ly5.1 or SWB recipients one day after transduction.
Western blot analysis
Total cellular protein extracts were prepared as described previously 27 and was size-separated by 12% sodium dodecyl sulfate-polyacryamide gel electrophoreis. After transfer to an A, and mast cell tryptase antibodies (DAKO Diagnostika, Hamburg, Germany) followed by the peroxidase-conjugated, mouse-specific Envison detection system (DAKO). Peroxidase activity was visualized by the help of commercial DAB or AEC substrates (DAKO). The same method was applied for the immuno-tracing of intracellular lysozyme (muramidase), but using a polyclonal rabbit anti-human lysozyme antibody (DAKO). For the quantitative determination of hematopoietic cells on cytospins, at least 300 cells were counted using a microscope front lens with a 100x magnification.
Results
Transduction of murine BM cells with eGFP and C/EBP (mut10)-expressing vectors
To test the effect of N-terminal C/EBP mutants on myeloid differentiation, the previously characterized CEBPA mutant 10 cDNA (mut10) 10 engraftment. This could be due to defects in homing, loss of self-renewal capacity, cell cycle block, increased apoptosis, or other cytotoxic effects.
Mut10 expression in murine BM cells does not block granulocytic differentiation but
alters the kinetics of differentiation and reduces the self-renewal potential.
As the in vivo studies did not allow us to make conclusions with regard to the effect of mut10 on differentiation, several in vitro assays were performed on infected Lin neg BM cells sorted for eGFP expression. We first performed colony assays under conditions that promote differentiation in granulocytic, monocytic, and erythroid differentiation. Consistent with a loss of self-renewal of early progenitors, significantly reduced numbers of colony forming cells (CFCs) were observed in FMEV-mut10 infected versus FMEV-GFP cultures (Table 1) .
However, no significant difference was observed in the ratio of lineage-specific CFCs,
suggesting that mut10 did not alter the differentiation potential along any specific lineage (Table 1) . Furthermore, microscopic examination of cells within mature colonies (day 10), confirmed the presence of mature forms of both myeloid (granulocyte / monocyte) and erythroid lineages. These results support the hypothesis that mut10 expression decreases the number of early progenitors, but does not impair differentiation. Although the absolute number of colonies were reduced as compared to controls, these colonies were morphologically identical to that obtained in control infected cultures. These results demonstrate that constitutive over-expression of the 30-kDa protein in these murine progenitors reduces the absolute number of colonies, but does not block granulocytic differentiation, even when stimulated solely by G-CSF, whose receptor is regulated by C/EBP .
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Interestingly, after 14 days of culture, when the control cultures contained almost exclusively macrophages and mast cells, cultures infected with mut10 showed continued differentiation of monocytic and granulocytic forms ( Figure 4A, B) . The altered kinetics of myelopoiesis in mut10-expressing cells was also evident in cultures containing GM-CSF alone (data not shown). Expression levels of eGFP in the FMEV-mut10 cultures were comparable to that in control cultures (data not shown), ruling out that a selection for low-expressing mut10 clones occurred. In conclusion, although myelocytic differentiation appears to initially increased in cultures expressing mut10, terminal differentiation of the culture is delayed. Taken together these results demonstrate that expression of mut10 cDNA and thus over-expression of the 30-kDa C/EBP protein does not block granulocytic differentiation of primary murine hematopoietic progenitors under any of the conditions tested, but alters the kinetics of the differentiation process. This is in contrast to cultures in which the Cebpa gene was excised, where our results confirm the importance of C/EBP in terminal granulopoietic differentiation.
Similarly to the human mut10, a murine C/EBP mutant does not block myelopoietic differentiation of murine progenitors but inhibits their clonogenic potential
For the studies described above, a cDNA derived from human cells was used.
Although the murine and human C/EBP proteins share 91.9% identity, it is conceivable that the human protein can not completely substitute for the mouse protein. We thus generated a murine equivalent of the human mut10 cDNA, which we termed mutAatII, and cloned it into a FMEV-YFP vector. As predicted and consistent with previous results of a similar mutant, 
Mut10 abrogates differentiation of human CD34 + CB cells
The effect of mut10 on the differentiation of murine progenitors is somewhat incongruous with the confirmed importance of C/EBP in myeloid differentiation and the dominantnegative effect of mut10 expression on wild-type C/EBP with respect to DNA-binding and transactivation of C/EBP regulated genes. 10 To determine if this was attributable to inherent differences between human and murine regulatory controls of differentiation that have evolved in these two species, we tested the effect of mut10 expression in primary human hematopoietic progenitors using the same retroviral vectors. CD34 + CB cells were efficiently infected with FMEV-eGFP and FMEV-mut10 (74 to 81% and 51 to 63%, respectively; range of three independent experiments) and sorted on the basis of eGFP expression. Notably, transcriptions levels of the FMEV-mut10 vector in human progenitors were equivalent to that observed in murine progenitors as measured by GFP fluorescence (x = 383 ± 40; n = 3 and x = 390 ± 98; n = 2, respectively; Figure 5A ). Western blot analysis also confirmed that expression levels of the 30-kDa in the FMEV-mut10 infected CD34 + CB cells were equivalent to that observed in infected murine BM cells ( Figure 5B ). Immediately after cell sorting, immature, blast-like cell elements predominated both FMEV-GFP and FMEV-mut10 infected CB cultures, although distinct differences could already be noted (Figure 5 C,D) . The number of immature erythroid cells (proerythroblasts and basophilic macroblasts) was significantly reduced in FMEV-mut10 cultures (7%) as compared to FMEV-GFP control cultures (30%). In addition, the nuclear cytoplasmic ratio was higher in cells transduced with FMEV-mut10 than in controls. Furthermore, the FMEVmut10 cultures were characterized by the presence of larger nuclei, the formation of more irregular nuclear contours (indented or lobulated) and delicate nuclear folds and creases, and the persistence of internuclear chromatin bridges and the development of pseudopods. After 14 days in differentiation medium (GM-CSF, IL3, and SCF), the differences became even more apparent ( Figure 5 E,F) . Whereas, control cultures exhibited a spectrum of maturing forms of normal erythroid (28%), monocytes / macrophages (38%), granulocytes (7%), and mast cells (27%), mut10-transduced cultures contained predominantly myeloblasts and neutrophilic (and fewer eosinophilic) promyelocytes with nuclear atypias (79%) admixed with some macrophages (15%) and rare erythroblasts.
Consistent with an immature myeloid phenotype, FACS analysis showed that all 9-day FMEV-mut10 infected cells were CD33+ (Figure 6 A, B) . Similarly, the FMEV-mut10 culture showed overall higher mean fluorescence intensity of CD34 antigen, as compared to differentiated control cells (Figure 6 C,D) . Only a minor population of the cells expressing mut10 were positive for CD14 antigen (20% versus 59% in controls), indicative of early to late stages of monocytic differentiation (Figure 6 E,F) . CD15 levels were similar to control infected cells (data not shown). Consistent with their morphology, these cells were negative for dendritic cell markers (CD1a and CD86; data not shown). 
Differentiation block observed in both erythroid and myeloid lineages
Colony assays of FMEV-GFP and FMEV-mut10 infected cultures were also performed to assess the cloning potential of the transduced cells and the differentiation potential under conditions that support differentiation in both myeloid and erythroid lineages. Although cells from control cultures gave rise to typical colonies from uni-to multipotent CFCs (Table 2) , almost all colonies from mut10-infected cultures were of a single morphology, closely resembling but distinct to CFU-G colonies in controls. After twelve days, colonies were disrupted and cells were spun onto glass slides and fixed. Whereas cells derived from FMEVeGFP-infected colonies were composed of mature erythrocytes, macrophages, and granulocytes, cells from FMEV-mut10 infected colonies resembled those from liquid cultures.
These results confirmed that both myeloid and erythroid differentiation was inhibited by expression of mut10. Four days after isolation of CD34 + CB cells, mock-infected or vector-infected cells sorted for GFP expression were plated in methylcellulose at two different cell concentrations and scored for colony formation and morphology after 11 days. Results are the average of a two independent experiments, each performed in triplicate. In addition, the clonogenic potential was impaired in these cells and they were no longer able to contribute to long-term repopulation in vivo. The murine equivalent (mutAatII) to the human mut10 C/EBP also did not abrogate differentiation but resulted in a similar loss of clonogenicity and shift in differentiation kinetics as the human protein, demonstrating that species-specific differences in the protein sequence were not responsible for the differential [40] [41] [42] Using microarrays to identify direct target genes of C/EBP in these two systems 7 may help to identify genes responsible for the differential dominant-negative effects of mut10.
Promiscuous expression of both myeloid and erythroid markers in differentiation-
In contrast to our study, two groups have recently shown that artificial dominantnegative C/EBP mutants blocked both monocytic and granulocytic differentiation but not erythroid differentiation in murine and human progenitors. 6, 38 Both of these dominantnegative mutants interfere with C/EBP transcriptional activation, either by actively repressing transcription or by forming stable heterodimers that abolish DNA binding. 6, 38 Thus, the inability of mut10 to efficiently repress transcription of all C/EBP target genes may explain why differentiation was not blocked in murine cells and why the differentiation block in human cells was distinct to that observed by Iwama et al. In their study, expression of the artificial dominant-negative C/EBP in human CD34 + CB cells resulted in the accumulation of dendritic cells and no block in erythropoiesis. 6 In addition to disrupting the transcriptional control of lineage-specific genes, C/EBP mutants may impair or alter differentiation by the disrupting cell cycle controls, a separable function of C/EBP 43 . Importantly, C/EBP-related transcription factors have been shown to regulate the balance between cell proliferation and mitotic growth arrest during terminal differentiation in several cell systems. 44 Although different mechanisms by which C/EBP inhibits proliferation have been proposed, including down-regulation of p21 and inhibition of cyclin-dependent kinases, 45, 46 recent studies have shown the importance of C/EBP -inhibition of the E2F pathway, and the consequent down-regulation of c-myc, in granulocytic differentiation. [47] [48] [49] Two domains in C/EBP are important for E2F inhibition, one that directly binds E2F and maps to the non-DNA-binding face of the basic region of B-ZIP domain [49] [50] [51] and a second domain that indirectly inhibits E2F and maps to the TE1 domain. 49 -51 The presence of both domains are critical for inducing granulocytic differentiation. 51, 52 Can some of the effects we observe with mut10 expression in hematopoietic progenitors be due to the sequestering of E2F by the B-ZIP domain, thereby inhibiting progression from G1
to the S phase of the cell cycle? It is tempting to speculate that an increased incidence of For personal use only. on September 14, 2017. by guest www.bloodjournal.org From that dictate lineage commitment is well established. [56] [57] [58] [59] As the bZIP domain of C/EBP is necessary for both PU.1 and c-Jun down-regulation, mut10 would also be expected to interact with these transcription factors. Thus it is tempting to speculate that interference with the extensive cross-talk between these lineage-specific transcription factors may underlie the block in multiple lineages observed in mut10-infected human progenitors.
In summary, our results clearly demonstrate that expression of an N-terminal C/EBP mutant disrupts myeloid differentiation in primary human progenitors, supporting the importance of such mutations in the development of AML. Furthermore, they demonstrate intrinsic differences between hematopoietic controls in mouse and human, signaling the need for caution in interpreting and transferring results between these two species. Further studies are required to test the domain in mut10 that is important for impairing myelopoiesis and to determine what mechanisms in mouse cells circumvent this differentiation block.
Understanding such mechanism may benefit the development of therapeutic molecules that override the differentiation block observed in AMLs.
